Compare DLPN & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | CODX |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 15.6M |
| IPO Year | N/A | 2017 |
| Metric | DLPN | CODX |
|---|---|---|
| Price | $1.52 | $0.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 37.7K | ★ 1.7M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $53,371,115.00 | $507,892.00 |
| Revenue This Year | $10.62 | N/A |
| Revenue Next Year | $13.78 | $18.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $0.75 | $0.23 |
| 52 Week High | $1.88 | $1.55 |
| Indicator | DLPN | CODX |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | 37.43 |
| Support Level | $1.41 | $0.24 |
| Resistance Level | $1.65 | $0.30 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 17.27 | 9.31 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.